参考文献/References:
[1]Alarid-Escudero F,Blaes AH,Kuntz KM.Trade-offs between efficacy and cardiac toxicity of adjuvant chemotherapy in early-stage breast cancer patients: do competing risks matter?[J].Breast J,2017,23(4):401-409.
[2]Huang J,Yan ZN,Rui YF,et al.Longitudinal rotation:a new way to detect the cardiotoxicity of anthracycline-based chemotherapy in breast cancer patients[J].Oncotarget,2017,8(41):70072-70083.
[3]Sim?es R,Silva LM,Cruz ALVM,et al.Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy:a narrative review[J].?Biomed Pharmacother,2018,107:989-996.
[4]Antolín S,Acea B,Albaina L,et al.Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy:efficacy data,cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution[J].Breast Cancer (Dove Med Press),2018,11:29-42.
[5] Bergamini C,Dolci G,Truong S,et al.Role of speckle tracking echocardiography in the evaluation of breast cancer patients undergoing chemotherapy:review and meta-analysis of the literature[J].Cardiovasc Toxicol,2019,19(6):485-492.
[6] Cai F,Luis MAF,Lin X,et al.Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer:Preventive strategies and treatment[J].Mol Clin Oncol,2019,11(1):15-23.
[7]Pistilli B,Marcellusi A,Latini L,et al.Cardiotoxicity related to long-term trastuzumab therapy in metastatic breast cancer:the potential role of treatment duration and cardiac risk factors[J].Breast J,2015,21(3):318-321.
[8] Du XL,Xia R,Liu CC,et al.Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer [published correction appears in Cancer.2009 Dec 15;115(24):5849-51][J].Cancer,2009,115(22):5296-5308.
[9] Koelwyn GJ,Lewis NC,Ellard SL,et al.Ventricular-arterial coupling in breast cancer patients after treatment with anthracycline-containing adjuvant chemotherapy[J].Oncologist,2016,21(2):141-149.
[10] Murtagh G,Lyons T,O’Connell E,et al.Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin:10-year follow-up[J].Breast Cancer Res Treat,2016,156(3):501-506.
[11] Boczar KE,Aseyev O,Sulpher J,et al.Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy[J].Echo Res Pract,2016,3(3):79-84.
[12] Cardinale D,Sandri MT,Martinoni A,et al.Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy[J].Ann Oncol.2002,13(5):710-715.
[13] Fumoleau P,Roché H,Kerbrat P,et al.Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer:French Adjuvant Study Group results[J].Ann Oncol,2006,17(1):85-92.
[14] Cardinale D,Sandri MT,Martinoni A,et al.Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy[J].Ann Oncol,2002,13(5):710-715.
[15] Barish R,Gates E,Barac A.Trastuzumab-induced cardiomyopathy[J].Cardiol Clin,2019,37(4):407-418.
[16] Yu AF,Singh JC,Wang R,et al.Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer[J].Oncologist,2017,22(6):642-647.
[17] Zambetti M,Montemurro F,Morandi P,et al.Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer:primary analysis of the SCHEARLY study[J].Eur J Cancer,2018,105:61-70.
[18] Brain E,Caillet P,de Glas N,et al.HER2-targeted treatment for older patients with breast cancer:An expert position paper from the International Society of Geriatric Oncology[J].J Geriatr Oncol.2019,10(6):1003-1013.
[19] Nowsheen S,Viscuse PV,O’Sullivan CC,et al.Incidence,diagnosis,and treatment of cardiac toxicity from trastuzumab in patients with breast cancer[J].Curr Breast Cancer Rep,2017,9(3):173-182.
[20] Jacquinot Q,Meneveau N,Chatot M,et al.A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3?months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab:design of the CARDAPAC study[J].BMC Cancer,2017,17(1):425.
[21] Jerusalem G,Lancellotti P,Kim SB.HER2+ breast cancer treatment and cardiotoxicity:monitoring and management[J].Breast Cancer Res Treat,2019,177(2):237-250.
[22] Marinko T,Borstnar S,Blagus R,et al.Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer[J].Radiol Oncol,2018,52(2):204-212.
[23] Nowsheen S,Aziz K,Park JY,et al.Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction[J].J Am Heart Assoc,2018,7(15):e008637.
[24] von Minckwitz G,Huang CS,Mano MS,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J].N Engl J Med,2019,380(7):617-628.
[25] Tanriverdi O,Meydan N,Barutca S.Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer:a pilot study[J].Med Oncol,2012,29(5):3265-3271.
[26] Mantarro S,Rossi M,Bonifazi M,et al.Risk of severe cardiotoxicity following treatment with trastuzumab:a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer[J].Intern Emerg Med,2016,11(1):123-140.
[27] Wang J,Xu R,Yuan H,et al.Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer:a pilot study[J] .Medicine (Baltimore),2019,98(26):e15872.
[28] Costa SD,Jackisch C,Thomssen C.Future roles of lapatinib in ErbB2-positive breast cancer:adjuvant and neoadjuvant trials[J].Breast Care (Basel),2010,5(s1):22-24.
[29] 冯泽豪,姜萌,卜军.心脏磁共振评价化疗所致心肌损伤的研究进展[J].心血管病学进展,2019,40(5):667-672.
相似文献/References:
[1]董新江 尚茹茹 刘晓红.乳腺癌放化疗引起心脏毒性的一级预防进展[J].心血管病学进展,2020,(1):78.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.021]
DONG Xinjiang,SHANG Ruru,?LIU Xiaohong.Primary Prevention of Cardiotoxicity Caused by Radiotherapy and Chemotherapy for Breast Cancer[J].Advances in Cardiovascular Diseases,2020,(8):78.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.021]
[2]唐雨琦 关旭敏 方凤奇 刘基巍 夏云龙.吉西他滨引起心脏毒性的研究现状[J].心血管病学进展,2020,(9):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
TANG Yuqi,GUAN Xumin,FANG Fengqi,et al.Cardiotoxicity Induced by Gemcitabine[J].Advances in Cardiovascular Diseases,2020,(8):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
[3]戴秋月 郎吉萍 吕萍 潘杭雨 郭志刚.他汀类药物抗乳腺癌作用的研究进展[J].心血管病学进展,2021,(9):776.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
DAI Qiuyue,LANG Jiping,LYU Ping,et al.Effect of Statins Against Breast Cancer[J].Advances in Cardiovascular Diseases,2021,(8):776.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[4]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5]郭良 黄鹤.恶性肿瘤相关心房颤动发病机制的研究进展[J].心血管病学进展,2022,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
GUO LiangHUANG He.Pathogenesis of Malignant Tumor-Related Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(8):870.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.002]
[6]杨仙 陈芸霖 殷跃辉 易鑫 杨敏 崔犇.女性乳腺癌相关性心房颤动的研究现状[J].心血管病学进展,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
YANG Xian,CHEN Yunlin,YIN Yuehui,et al.Research Status of Female Breast Cancer Associated Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]